Since its listing on October 27, 2021, the stock price of Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) new shares has increased by 940.71% due to the hot spot of mosadon covid-19 Oral Medicine , from November 5 to November 12, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) within six trading days recorded five 20cm trading limits due to the hot spot of domestic covid-19 Oral Medicine , the company’s share price has ushered in another wave of speculation recently. Recently, two 20cm trading limits have been recorded in five trading days .
After hours today, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) received a letter of concern, asking to list the product name and corresponding end customers of azvudine API produced by the company, and explain the ownership of relevant products and corresponding end drugs. In addition, it is required to explain whether the company’s reply on the ” interactive easy ” platform exists the concept of speculation hot spots and cooperates with the reduction of shareholders .
According to public information, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) is a high-tech enterprise engaged in the R & D, production and sales of chemical APIs, pharmaceutical intermediates and other products.
After significant progress has been made in covid-19 oral specific drug developed by multinational pharmaceutical giants, the research and development of domestic drugs of the same type has attracted extensive attention. At present, real creatures and Shanghai Junshi Biosciences Co.Ltd(688180) covid-19 oral drugs have the fastest progress, both of which are in phase III clinical trials .
It is reported that azvudine has good anti covid-19 virus activity at the cellular and animal levels .
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) replied on interactive easy that Xinxiang pharmaceutical, a subsidiary of is the manufacturer of azvudine API and has been supplied to real organisms .
Analysts believe that given the severity of the current overseas epidemic, “covid-19 vaccine + specific drug” is considered to be the best means of epidemic prevention and control .
According to the analysis of AVIC securities, according to the announcement and annual report released by Pfizer, the price of a single course of paxlovid is $529, it is estimated that the revenue of covid-19 oral medicine will reach $22 billion in 2022. Covid-19 oral medicine, as the last puzzle in the current covid-19 treatment industry chain, has a broad market prospect .
Tuoxin drug product uridine is the raw material for the production of eidd-2801, and eidd-2801 is also the raw material for molnupiravir (mk-4482 / eidd-2801), which is the second covid-19 oral drug authorized by the US FDA for emergency use (only one day difference between the two) after Pfizer.
In fact, as early as November 2021, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) rubbed off a wave of heat , before molnupiravir, an oral drug of MSD covid-19, had received an urgent authorization application (EUA). At that time, the company said on the interactive platform that its uridine is the raw material for the production of eidd-2801, which is the raw material for the production of covid-19 oral drug molnupiravir.
